Literature DB >> 30519730

Institutional patient accrual volume and the treatment quality of I‑125 prostate seed implantation in a Japanese nationwide prospective cohort study.

Katsumasa Nakamura1, Saiji Ohga2, Atsunori Yorozu3, Shiro Saito4, Takashi Kikuchi5, Takushi Dokiya6, Masanori Fukushima5, Hidetoshi Yamanaka7.   

Abstract

PURPOSE: It is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study.
METHODS: From July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters).
RESULTS: In the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90%, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions.
CONCLUSIONS: Our findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.

Entities:  

Keywords:  Brachytherapy; Dose-volume histogram; Institutional experience; Prostate cancer; Treatment quality

Mesh:

Substances:

Year:  2018        PMID: 30519730     DOI: 10.1007/s00066-018-1407-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

Review 1.  Provider volume and outcomes for oncological procedures.

Authors:  S D Killeen; M J O'Sullivan; J C Coffey; W O Kirwan; H P Redmond
Journal:  Br J Surg       Date:  2005-04       Impact factor: 6.939

2.  Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?

Authors:  Badrinath R Konety; Veerasathpurush Allareddy; Sanjukta Modak; Brian Smith
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

3.  Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.

Authors:  Carl Salembier; Pablo Lavagnini; Philippe Nickers; Paola Mangili; Alex Rijnders; Alfredo Polo; Jack Venselaar; Peter Hoskin
Journal:  Radiother Oncol       Date:  2007-02-26       Impact factor: 6.280

4.  High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.

Authors:  Claudio Jeldres; Nazareno Suardi; Fred Saad; Francesco Montorsi; Shahrokh F Shariat; Paul Perrotte; Naeem Bhojani; Jochen Walz; Georg C Hutterer; Markus Graefen; Luc Valiquette; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2007-11-06       Impact factor: 20.096

5.  Analysis of the Pro-Qura Database: rectal dose, implant quality, and brachytherapist's experience.

Authors:  Christopher R Loiselle; Musaddiq Waheed; John Sylvester; Zachariah A Allen; Peter D Grimm; Steven Eulau; Wayne M Butler; Gregory S Merrick
Journal:  Brachytherapy       Date:  2008-12-03       Impact factor: 2.362

Review 6.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.

Authors:  S Nag; D Beyer; J Friedland; P Grimm; R Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

7.  Potential role of various dosimetric quality indicators in prostate brachytherapy.

Authors:  G S Merrick; W M Butler; A T Dorsey; J H Lief
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

8.  Provider case volume and outcomes following prostate brachytherapy.

Authors:  Aileen B Chen; Anthony V D'Amico; Bridget A Neville; Ewout W Steyerberg; Craig C Earle
Journal:  J Urol       Date:  2008-11-13       Impact factor: 7.450

9.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Authors:  Mira Keyes; Stacy Miller; Veronika Moravan; Tom Pickles; Michael McKenzie; Howard Pai; Mitchell Liu; Winkle Kwan; Alexander Agranovich; Ingrid Spadinger; Vincent Lapointe; Ross Halperin; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-26       Impact factor: 7.038

10.  Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.

Authors:  Michael J Zelefsky; Yoshiya Yamada; Gil'ad N Cohen; Neha Sharma; Alison M Shippy; David Fridman; Marco Zaider
Journal:  Radiother Oncol       Date:  2007-08-10       Impact factor: 6.280

View more
  2 in total

1.  Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects.

Authors:  Matthias Moll; Christopher Paschen; Alexandru Zaharie; Florian Berndl; Gregor Goldner
Journal:  Strahlenther Onkol       Date:  2020-07-08       Impact factor: 3.621

2.  Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.

Authors:  Matthias Moll; Andreas Renner; Christian Kirisits; Christopher Paschen; Alexandru Zaharie; Gregor Goldner
Journal:  Strahlenther Onkol       Date:  2021-08-05       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.